<DOC>
	<DOCNO>NCT01334606</DOCNO>
	<brief_summary>The primary purpose study demonstrate BD 4mm x 32G Ultra-Fine Nano pen needle provide equivalent glycemic control BD 8mm x 31G Ultra-Fine short pen needle measure fructosamine ( FRU ) among Lantus® , Levemir® , and/or NPH user take one single daily injection great 40 unit insulin . Glycemic control , injection pain , leakage , preference , comfort , parameter compare 4mm x 32G 8 mm x 31 G pen needle three week use device . Sufficient number subject take Lantus® basal insulin enrol allow pre-specified analysis subgroup .</brief_summary>
	<brief_title>Evaluation 4mmx32G Pen Needle Injection Basal Insulin Doses Above 40 Units</brief_title>
	<detailed_description>This open-label , randomized two period crossover study . Each subject 's participation expect last seven week include brief enrolment period follow two consecutive three week treatment period ( Period 1 Period 2 ) . In Period 1 , subject use first assign study pen needle ( either 4mm Nano 8mm Short ) self-administer daily pen-based diabetes medication . Upon completion Period 1 , subject switch alternate pen needle Period 2 . The randomization schedule determine order pen needle use . Blood sample determination fast blood glucose serum fructosamine concentration collect baseline ( Visit 2 ) end Period 1 ( Visit 3 ) Period 2 ( Visit 4 ) . Blood sample analyze central laboratory .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus Have use pen device diabetes diabetesrelated medication least one month prior screen Use pen device selfadminister great 40 unit Lantus , Levemir , and/or NPH one single injection . For split dos , least one injection must deliver 40 unit . Documented hemoglobin A1c ( HbA1c ) 5.5 % 9.5 % , inclusive Self monitor blood glucose daily memory blood glucose meter , willing least twice per day duration study On stable diabetes regimen ( insulin noninsulin med , diet exercise ) least 1 month prior screen Able read , write follow instruction English Current administration insulin pump . Current use syringe inject insulin diabetesrelated medication Participation clinical study BDDC08011 DBC10SQUIR05 History intravenous drug abuse . Current status history medical condition would contraindicate treatment study product condition , opinion Investigator , would place subject risk potentially confound interpretation study result ( i.e. , recent history ketoacidosis , hypoglycemic unawareness , etc ) . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>diabetes</keyword>
	<keyword>pen needle</keyword>
	<keyword>basal insulin</keyword>
	<keyword>long-acting insulin</keyword>
</DOC>